The Slice is Right

The Slice is Right

Kalorama Information is pleased to announce that you can now buy slices of our industry-leading market research reports.


Germany Becomes Biosimilar HotSpot

Germany Becomes Biosimilar HotSpot

A more efficient regulatory pathway, large market and pricing pressures has made Germany the lead market for biosimilars. These are the close "generic like" replicas of biological drugs. Kalorama Information's new report details markets by country and finds the leading EU market has an advantage on other world pharmaceutical markets.


For Major Biopharma Products, Competition is Coming

For Major Biopharma Products, Competition is Coming

Biosimilars- close replicas of profitable biopharmaceutical drugs, are arriving to the U.S. market. This according to Kalorama Information's new market research study. There are dozens of companies developing similar biotherapeutics. And although they've been slow to develop in the U.S. market, there's more world development and signs of change.

  • by Bruce Carlson
  • November 15 2017


Oncology Remains Most Active, Highest-Growth Area for LDTs

Oncology Remains Most Active, Highest-Growth Area for LDTs

There will be a robust market for LDTs because there aren't enough commercial test solutions for the clinical needs of labs. So predicts a report from Kalorama.